aXichem AB (publ), a pioneer in the development and marketing of natural analogue industrial chemicals, is pleased to announce new orders for aXivite® from Uriach, a renowned and expanding European pharmaceutical company. The order is related to the production of a new melatonin formula for Uriach’s brand Aquilea® featuring aXivite®. The first order was announced in November 2023, and with the additional orders placed, the total order value from Uriach, to date, amounts to about 60,000 Euro.
“We're delighted with this progress and eager to further develop our collaboration with Uriach on the Aquilea product with aXivite. This partnership offers valuable insights into phenylcapsaicin's role as a bio-enhancer and its market potential in health and wellness”, says Torsten Helsing, CEO of aXichem.
The Supply and Research Agreement with Uriach, signed in June 2023, grants Uriach exclusive rights to a melatonin formulation with aXivite in Spain, Portugal, Germany, Austria, and Romania, with a commitment to an annual minimum purchase of 400,000 Euro. In April 2024 Spain will be the first market to experience Aquilea's new formula containing aXivite. The roll-out will then continue market by market, further expanding the reach and impact of aXivite in the dietary supplement market.
About phenylcapsaicin and aXivite aXichem's proprietary molecule, phenylcapsaicin, combines the naturally occurring phenyl group with capsaicin, connected by a triple bond. The result is an innovative natural analog capsaicin with high purity, which in several studies has been shown to have the same health-promoting properties, as well as some unique benefits, as natural capsaicin. Phenylcapsaicin is approved under Novel Food in the EU and GRAS Food in the USA and is marketed for dietary supplements and functional foods under the brand name aXivite.
The information was submitted, through the care of the contact person below, for publication on 10 January 2024, at 09:30 CET.